AAIC 2026: Clinical Trials and Drug Development

📖 Wiki Page

event675 wordssynced 2026-04-02

Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK

Overview

flowchart TD events_aaic_2026_clinical_tria["AAIC 2026: Clinical Trials and Drug Development"] style events_aaic_2026_clinical_tria fill:#4fc3f7,stroke:#333,color:#000 events_aaic_2026_cli_0["Phase 2/3 Trial Results"] events_aaic_2026_clinical_tria -->|"includes"| events_aaic_2026_cli_0 style events_aaic_2026_cli_0 fill:#81c784,stroke:#333,color:#000 events_aaic_2026_cli_1["Anti-Amyloid Therapies"] events_aaic_2026_clinical_tria -->|"includes"| events_aaic_2026_cli_1 style events_aaic_2026_cli_1 fill:#ef5350,stroke:#333,color:#000 events_aaic_2026_cli_2["Anti-Tau Therapies"] events_aaic_2026_clinical_tria -->|"includes"| events_aaic_2026_cli_2 style events_aaic_2026_cli_2 fill:#ffd54f,stroke:#333,color:#000 events_aaic_2026_cli_3["Neuroprotective Agents"] events_aaic_2026_clinical_tria -->|"includes"| events_aaic_2026_cli_3 style events_aaic_2026_cli_3 fill:#ce93d8,stroke:#333,color:#000 events_aaic_2026_cli_4["Novel Therapeutic Compounds"] events_aaic_2026_clinical_tria -->|"includes"| events_aaic_2026_cli_4 style events_aaic_2026_cli_4 fill:#4fc3f7,stroke:#333,color:#000 events_aaic_2026_cli_5["Small Molecule Approaches"] events_aaic_2026_clinical_tria -->|"includes"| events_aaic_2026_cli_5 style events_aaic_2026_cli_5 fill:#81c784,stroke:#333,color:#000

...

Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK

Overview

Mermaid diagram (expand to render)

AAIC 2026 features comprehensive coverage of clinical trial results and drug development programs for Alzheimer's disease and related dementias. This page captures Phase 2/3 trial results, novel therapeutic compounds, and emerging treatment strategies presented at the conference["@cummings2024"].

Phase 2/3 Trial Results

Anti-Amyloid Therapies

Lecanemab (Leqembi)

CLARITY-AD Open Label Extension: Long-term effectiveness data
ARIA management protocols: Real-world experience
Biomarker correlates: Plasma p-tau217 as treatment response marker

Donanemab (Kisunla)

TRAILBLAZER-ALZ 3: Preclinical AD prevention trial updates
TRAILBLAZER-ALZ 2 OLE: Extended follow-up data
Tau burden stratification: Impact on treatment response

Gantenerumab

GRADUATE trials: Complete results and analyses
Lessons learned: Dose optimization and plaque clearance

Anti-Tau Therapies

Tau Immunotherapies

RNIC (SPRING): Anti-tau antibody in Phase 2
J&J programs: Multiple tau-targeted approaches
AC Immune: Novel tau vaccine candidates

Tau Aggregation Inhibitors

Methylthioninium chloride (MTC): Phase 3 results
Small molecule modulators: Clinical development status

Neuroprotective Agents

GLP-1 Receptor Agonists

Exenatide: Phase 2 cognitive outcomes
Semaglutide: Phase 3 EMERALD program
Tirzepatide: Dual GIP/GLP-1 in AD

Mitochondrial Protectants

Cytochrome c oxidase modulators: Phase 1/2 results
NAD+ precursors: NIC5-15 and NMN trials
Antioxidant approaches: Mitochondrial-targeted antioxidants

Novel Therapeutic Compounds

Small Molecule Approaches

| Compound | Target | Phase | Company |
|----------|--------|-------|---------|
| AL108 (PNQX) | PDE9 inhibitor | Phase 2 | Pfizer |
| ACD-855 | Tau aggregation | Phase 1 | Acumen |
| JNJ-63733657 | Tau antibody | Phase 2 | J&J |
| LY3374289 | Anti-Aβ antibody | Phase 1 | Eli Lilly |

Gene Therapy Approaches

AAV-mediated gene delivery: BDNF, NGF delivery
Antisense oligonucleotides: APP and tau reduction
CRISPR-based approaches: Emerging preclinical programs

Cell-Based Therapies

Stem cell approaches: MSC transplantation trials
Microglial modulation: Targeted cell therapies
Biologic delivery: Novel delivery mechanisms

Treatment Strategies

Combination Therapy Approaches

AAIC 2026 highlights the shift toward combination therapies:

Anti-amyloid + anti-tau: Simultaneous pathology targeting

Anti-amyloid + neuroprotective: Complementary mechanisms

Disease-modifying + symptomatic: Comprehensive treatment

Biomarker-Guided Patient Selection

Plasma biomarkers: p-tau217, p-tau181, GFAP
Tau PET: Patient stratification for anti-tau trials
Genetic stratification: APOE and polygenic risk scores

Precision Medicine Approaches

Autosomal dominant AD: DIAN-TU trial updates
Down syndrome: Alzheimer's prevention in trisomy 21
Early-onset AD: Targeted therapeutic approaches

Repurposed Drug Programs

Priority Candidates

| Drug | Original Indication | AD Target | Phase |
|------|---------------------|-----------|-------|
| Metformin | Diabetes | Insulin sensitization | Phase 3 |
| Losartan | Hypertension | Vascular protection | Phase 2 |
| Atorvastatin | Hyperlipidemia | Cholesterol modulation | Phase 3 |
| Valacyclovir | Herpes | Antiviral approach | Phase 2 |

Trial Results

SPRINT-MIND: Blood pressure and cognitive outcomes
EXERT: Exercise in preclinical AD
MIND Diet: Nutritional intervention results

Clinical Trial Design Innovations

Digital Endpoints

Smartphone-based cognitive assessments
Remote monitoring technologies
Digital biomarker collection

Adaptive Trial Designs

Platform trials for AD
Master protocols
Bayesian approaches

Pragmatic Trials

Real-world evidence generation
Registry-based trials
Embedded trials

Notable Sessions

Late-Breaking Research

Major Phase 3 trial results
Novel mechanism presentations
First-in-human data

Symposia

"Clinical Trial Design in the Era of Biomarkers"
"Combination Therapy: Rationale and Evidence"
"Repurposing Successes and Failures"

[Anti-Amyloid Antibody Clinical Trials](/therapeutics/anti-amyloid-antibody-clinical-trials)](/clinical-trials)
[Anti-Tau Immunotherapy Programs](/therapeutics/anti-tau-immunotherapy-programs)](/therapeutics)
[GLP-1 Receptor Agonists in Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)](/therapeutics)
[Alzheimer's Disease Clinical Trials](/clinical-trials)

References

[Cummings J, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement. 2024 (2024)](/[DOI:10.1002/alz.13850](https://doi.org/10.1002/alz.13850))

[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 (2023)](/[DOI:10.1056/NEJMoa2212948](https://doi.org/10.1056/NEJMoa2212948))

[Sims JR, et al., Donanemab in Early Alzheimer's Disease. N Engl J Med. 2023 (2023)](/[DOI:10.1056/NEJMoa2304710](https://doi.org/10.1056/NEJMoa2304710))

[Budd Haeberlein S, et al., Lecanemab: Emergence of a New Treatment. JAMA Neurol. 2023 (2023)](/[DOI:10.1001/jamaneurol.2023.0118](https://doi.org/10.1001/jamaneurol.2023.0118))

📖 View canonical wiki page →

AAIC 2026: Clinical Trials and Drug Development

Overview

Overview

Phase 2/3 Trial Results

Anti-Amyloid Therapies

Lecanemab (Leqembi)

Donanemab (Kisunla)

Gantenerumab

Anti-Tau Therapies

Tau Immunotherapies

Tau Aggregation Inhibitors

Neuroprotective Agents

GLP-1 Receptor Agonists

Mitochondrial Protectants

Novel Therapeutic Compounds

Small Molecule Approaches

Gene Therapy Approaches

Cell-Based Therapies

Treatment Strategies

Combination Therapy Approaches

Biomarker-Guided Patient Selection

Precision Medicine Approaches

Repurposed Drug Programs

Priority Candidates

Trial Results

Clinical Trial Design Innovations

Digital Endpoints

Adaptive Trial Designs

Pragmatic Trials

Notable Sessions

Late-Breaking Research

Symposia

Related NeuroWiki Content

See Also

References